Abstract In the present study, multiple chemotherapeutic agent-related genetic polymorphisms, including dihydropyrimidine dehydrogenase (DPD) IVS14þ1 G>A, UGT1A1 3156 G>A, and UDP-glucuronosyltransferase (UGT)1A1 28 tandem repeats, were analyzed in patients with colorectal cancer and studied in correlation with the clinical features of those patients. The genotypes from 273 patients with stages IeIV colorectal cancer who underwent operations were determined by means of polymerase chain reaction-restriction fragment length polymorphism. The results showed that the genotype distribution of DPD GG, UGT1A1 3156 GG, and UGT1A1 28 tandem repeats 5/6 or 6/6 in Taiwanese subjects were 98.4%, 82.2%, and 80.6%,
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Introduction
Genetic polymorphisms in drug-metabolizing enzymes have been linked to interindividual differences in the toxicity and efficacy of medication.
1 A pharmacogenetic approach may be an innovative strategy for optimizing chemotherapy in patients with advanced colorectal cancer. We analyzed several chemotherapeutic agent-related genetic polymorphisms, including dihydropyrimidine dehydrogenase (DPD) IVS14þ1 G>A, UGT1A1 3156 G>A, and UDPglucuronosyltransferase (UGT) 1A1 28tandem repeats in Taiwanese colorectal cancer patients. 
Materials and methods
Consecutive 273 patients were prospectively enrolled in surgical units in Taiwan. Patients were required to have cytologically/histologically confirmed colorectal cancer disease. Blood samples were collected from these patients having stages IeIV colorectal cancer, and the DNA was isolated. A polymerase chain reaction-restriction fragment length polymorphism method was used to detect the frequency of the genotypes in our population. The associations of each genetic polymorphism with clinicopathological data of patients were further analyzed.
Results
Results showed that the genotype distribution of DPD GG, UGT1A1 3156 GG, and UGT1A1 28 tandem repeats 5/6 or 6/6 in Taiwanese subjects were 98.4%, 82.2%, and 80.6%, respectively. When analyzed jointly, a significant correlation was observed between vascular invasion in patients with genetic polymorphisms ofDPDGG, UGT1A13156GG, and UGT1A1 28 repeat 5/6 or 6/6 (OR: 2.236, p Z 0.015). There was a statistical correlation between vascular invasion and tumor invasion, lymph node metastasis, cancer stage, differentiation, perineural invasion, and survival (all p < 0.05).
Discussion
DPD is a critical enzyme in the catabolism of 5-fluorouracil (5-FU), a drug frequently used in cancer therapy. One of the possible causes of severe 5-FU toxicity is genetic polymorphisms in the DPD gene, such as IVS14þ1 G > A. 3 Irinotecan unexpectedly causes severe toxicity of leukopenia or diarrhea. It is metabolized to form active SN-38, which is further conjugated and detoxified by UGT1A1 enzyme. Genetic polymorphisms of the UGT1A1 would affect an interindividual variation of the toxicity by irinotecan via the alternation of bioavailability of SN-38. 2 The results of the present study highly suggest that DPD GG, UGT1A1 3156GG, and UGT1A1 28 repeat 5/6 or 6/6 genotypes and vascular invasion could be prognostic factors for Taiwanese patients with colorectal cancer.
